NVS - Spark Newswire

1 minute read

Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings

September 23, 6:48 AM

Citius Pharmaceuticals Inc (NASDAQ:CTXR) collaborated with the University of Pittsburgh for I/ONTAK (denileukin diftitox or E7777) in combination with Merck & Company,…

CTXR

56 minute read

Options

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

September 22, 2:17 PM

On Thursday, 1076 companies hit new 52-week lows.

$APE

5 minute read

Novartis Unveils New Strategy Focused On US-First, Eight Blockbuster Brands

By Vandana Singh

September 22, 6:22 AM

Novartis AG (NYSE:NVS) has revealed insights into the updated company strategy. The company said that a ‘US-first’ mindset, increasing the…

NVS

4 minute read

Novartis Announced Focusing Strategy on Five Core Therapeutic Areas, Key Technology Platforms, and U.S.; Said Will Continue to Deliver Improved Financials With +4% Sales CAGR Through 2027 and Core Op Inc Margin ~40%+ in Mid-long Term

By Charles Gross

September 22, 4:46 AM

Novartis executives are meeting investors and industry analysts in Basel today, sharing insights into the updated company strategy at the annual Meet Novartis Management event.

NVS

19 minute read

Options

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

September 21, 12:42 PM

On Wednesday, 340 stocks hit new 52-week lows.

$APE

1 minute read

Novartis To Petition US Supreme Court To Uphold Patent Validity For Multiple Sclerosis Drug, Gilenya

By Vandana Singh

September 21, 7:41 AM

Swiss drug major Novartis AG (NYSE:NVS) plans to petition the U.S. Supreme Court to uphold the validity of the Gilenya (fingolimod) dosing…

NVS

2 minute read

Legal
News

Novartis Announced Plans to Petition the U.S. Supreme Court to Uphold Validity of the Gilenya Dosing Regimen Patent

By Charles Gross

September 21, 4:54 AM

Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) has denied its petition to rehear the negative decision regarding the validity of US Patent No. 9,187,405, covering a dosing regimen for 0.5mg Gilenya. Novartis plans to file a petition seeking further review of the CAFC's decision with the US Supreme Court.

NVS

2 minute read

News

Novartis Unit Sandoz Announced ROSALIA Phase I/III Clinical Trial Study Met Primary Endpoints

By Charles Gross

September 19, 4:55 AM

Sandoz today announces further progress on its biosimilar pipeline, with the release of positive results from the integrated ROSALIA Phase I/III clinical trial study for its proposed biosimilar denosumab.

NVS

5 minute read

Feed Symbols: NVS

Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings

Stocks That Hit 52-Week Lows On Thursday

Top Financial Media Stories Thursday, September 22: Facebook Sued For Bypassing Apple Privacy Rules, Walmart Slows Hiring Plans Ahead Of Holiday Season, China Blames US For Northwestern Polytechnical University Hack And More..

Novartis Unveils New Strategy Focused On US-First, Eight Blockbuster Brands

Novartis Announced Focusing Strategy on Five Core Therapeutic Areas, Key Technology Platforms, and U.S.; Said Will Continue to Deliver Improved Financials With +4% Sales CAGR Through 2027 and Core Op Inc Margin ~40%+ in Mid-long Term

Stocks That Hit 52-Week Lows On Wednesday

Novartis To Petition US Supreme Court To Uphold Patent Validity For Multiple Sclerosis Drug, Gilenya

Novartis Announced Plans to Petition the U.S. Supreme Court to Uphold Validity of the Gilenya Dosing Regimen Patent

Novartis Unit Sandoz Announced ROSALIA Phase I/III Clinical Trial Study Met Primary Endpoints

Top Financial Media Stories Thursday, September 15: US Railway Companies, Unions Reach Tentative Agreement, Tesla To Wind Down Stores In China’s Flashy Malls, Netflix Could Face Legal Action Over South Korean Crime Drama And More..